65,437 trials
Multiple Myeloma
Primary: Progression Free Survival (PFS) — 10.25; 4.70 Months — p=0.0043
Atrial Fibrillation
Primary: Stroke Overall (Hemorrhagic, Ischemic, Uncertain) — 0.52; 0.69; 0.46; 0.36 Event Rate in 100 person-years — p=0.0844
Alcohol or Other Drugs Use
Primary: Mean Number of Days Used Primary Drug (NumDU) — 8.5; 5.0 days
Alzheimer's Type Dementia
Primary: Number of Participants With Medication Continuation — 36; 39 participants
Hypertension
Primary: Percentage of Participants Who Had One or More Adverse Events — 8.34 Percentage of Participants
Diabetes Mellitus, Type 1
Primary: Change in Averaged Mean Far Wall Common Carotid Artery Intima-media Thickness (cIMT) — 0.773; 0.791; 0.782; 0.788 mm
Regret
Primary: Difference in Consideration of Regret — 62; 69 participants reported regret played role
Blood Pressure
Primary: Performance Comparison: NIBP Forearm Cuff Using SuperStat Algorithm vs. Invasive Radial Blood Pressure Reading — -0.94; 1.39 mmHg
Insomnia
Primary: Number of Participants Completing 5 Behavioral Treatment Sessions — 63; 70 Participants — p==.120
Hypercholesterolemia
Primary: Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinite Time (AUCinf) — 175.9; 198.9; 160.3 micrograms*day/milliliter (mcg*day/mL)
Anxiety
Primary: Penn State Worry Questionnaire - A (PSWQ-A) at 6 Months — 26.73; 26.25; 22.04; 23.04 units on a scale — p=0.77
Cardiac Catheterisation
Primary: Pain Assessment Using Visual Analogue Scale — 24.75; 24.74 score on a scale
Depression · Anxiety
Primary: Adherence to the Mobile Application Intervention — 56; 56; 56; 56 days — p=0.3
Frontotemporal Dementia · Right Sided Cerebral Hemisphere Cerebrovascular Accident
Primary: Change in Social-Cognitive Functioning — 34.6; 34.6; 35.3; 34.6 Number Correct
Huntington's Disease
Primary: Number of Participants With Treatment-related Adverse Events (TEAEs) — 12; 3; 6; 6 Participants